ScholarIQanswers from OpenAlex & ORCID
Roy Fleischmann
ResearcherPublications, citations & collaboration network
Roy Fleischmann is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Roy Fleischmann have?
ScholarIQindexed works
Roy Fleischmann has 490 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Roy Fleischmann have?
ScholarIQcitation count
Roy Fleischmann has 32,688 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Roy Fleischmann?
ScholarIQh-index
Roy Fleischmann has an h-index of 80 in OpenAlex.
What is the i10-index of Roy Fleischmann?
ScholarIQi10-index
Roy Fleischmann has an i10-index of 224 in OpenAlex.
What is the ORCID of Roy Fleischmann?
ScholarIQorcid
The ORCID for Roy Fleischmann is on the source record.
What is the OpenAlex record for Roy Fleischmann?
ScholarIQopenalex
The OpenAlex for Roy Fleischmann is on the source record.
What are the most-cited papers on Roy Fleischmann?
ScholarIQmost cited works
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Roy Fleischmann, Joel M. Kremer, John J. Cush, Hendrik Schulze‐Koops, Carol A. Connell, John Bradley, David Gruben, Gene V. Wallenstein, Samuel H. Zwillich, Keith S. Kanik
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
Ronald van Vollenhoven, Roy Fleischmann, Stanley Cohen, Eun Bong Lee, Juan A. García Meijide, Sylke Wagner, Šárka Forejtová, Samuel H. Zwillich, David Gruben, Tamás Koncz, Gene V. Wallenstein, Sriram Krishnaswami, John Bradley, Bethanie Wilkinson
Tofacitinib versus Methotrexate in Rheumatoid Arthritis
Eun Bong Lee, Roy Fleischmann, Stephen Hall, Bethanie Wilkinson, John Bradley, David Gruben, Tamás Koncz, Sriram Krishnaswami, Gene V. Wallenstein, Chuanbo Zang, Samuel H. Zwillich, Ronald van Vollenhoven
Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study
Désirée van der Heijde, Yoshiya Tanaka, Roy Fleischmann, Edward Keystone, Joel M. Kremer, Cristiano A. F. Zerbini, Myrna Cardiel, Stanley Cohen, Peter Nash, Yeong Wook Song, Dana Tegzová, Bradley T. Wyman, David Gruben, Birgitta Benda, Gene V. Wallenstein, Sriram Krishnaswami, Samuel H. Zwillich, John Bradley, Carol A. Connell, and the ORAL Scan Investigators
Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis
Joel M. Kremer, Zhanguo Li, Stephen Hall, Roy Fleischmann, Mark C. Genovese, E. Martín‐Mola, John D. Isaacs, David Gruben, Gene V. Wallenstein, Sriram Krishnaswami, Samuel H. Zwillich, Tamás Koncz, Richard J. Riese, John Bradley